Denali Therapeutics Inc. (NASDAQ:DNLI) Given Average Rating of “Buy” by Analysts

Denali Therapeutics Inc. (NASDAQ:DNLI) has been assigned an average recommendation of “Buy” from the eleven research firms that are covering the firm, Marketbeat reports. Eleven analysts have rated the stock with a buy recommendation. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $52.20.

A number of brokerages have issued reports on DNLI. TheStreet lowered shares of Denali Therapeutics from a “c-” rating to a “d+” rating in a research note on Wednesday, September 6th. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Denali Therapeutics in a report on Wednesday. B. Riley started coverage on shares of Denali Therapeutics in a report on Wednesday, September 6th. They set a “buy” rating and a $38.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $105.00 target price on shares of Denali Therapeutics in a research note on Thursday, August 31st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $35.00 target price (down previously from $85.00) on shares of Denali Therapeutics in a research note on Tuesday, October 24th.

Insider Transactions at Denali Therapeutics

In other news, Director Vicki L. Sato sold 1,666 shares of the company’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $20.66, for a total transaction of $34,419.56. Following the transaction, the director now directly owns 128,039 shares in the company, valued at $2,645,285.74. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Vicki L. Sato sold 1,666 shares of the business’s stock in a transaction that occurred on Monday, October 16th. The shares were sold at an average price of $20.66, for a total transaction of $34,419.56. Following the completion of the sale, the director now directly owns 128,039 shares of the company’s stock, valued at $2,645,285.74. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Steve E. Krognes sold 1,419 shares of the business’s stock in a transaction that occurred on Monday, August 21st. The stock was sold at an average price of $22.60, for a total transaction of $32,069.40. Following the sale, the director now directly owns 145,799 shares of the company’s stock, valued at $3,295,057.40. The disclosure for this sale can be found here. Over the last three months, insiders have sold 22,700 shares of company stock worth $519,131. Corporate insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently bought and sold shares of the company. PNC Financial Services Group Inc. boosted its holdings in Denali Therapeutics by 85.2% during the fourth quarter. PNC Financial Services Group Inc. now owns 1,669 shares of the company’s stock worth $46,000 after purchasing an additional 768 shares during the last quarter. China Universal Asset Management Co. Ltd. increased its position in Denali Therapeutics by 34.1% during the first quarter. China Universal Asset Management Co. Ltd. now owns 1,851 shares of the company’s stock worth $43,000 after acquiring an additional 471 shares during the period. Assetmark Inc. increased its position in Denali Therapeutics by 49.1% during the third quarter. Assetmark Inc. now owns 2,148 shares of the company’s stock worth $44,000 after acquiring an additional 707 shares during the period. Sandia Investment Management LP bought a new position in Denali Therapeutics during the fourth quarter worth about $70,000. Finally, Point72 Middle East FZE bought a new position in Denali Therapeutics during the fourth quarter worth about $100,000. Institutional investors own 78.04% of the company’s stock.

Denali Therapeutics Trading Down 5.2 %

NASDAQ DNLI opened at $16.22 on Friday. The company has a market cap of $2.24 billion, a PE ratio of -16.72 and a beta of 1.19. Denali Therapeutics has a 1 year low of $15.92 and a 1 year high of $33.31. The stock’s 50-day moving average price is $21.05 and its two-hundred day moving average price is $25.59.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.72) EPS for the quarter, topping analysts’ consensus estimates of ($0.81) by $0.09. Denali Therapeutics had a negative net margin of 36.51% and a negative return on equity of 11.54%. The firm had revenue of $1.30 million during the quarter, compared to analyst estimates of $11.16 million. During the same quarter last year, the business posted ($0.84) EPS. The company’s revenue was down 63.9% on a year-over-year basis. Research analysts forecast that Denali Therapeutics will post -1.16 EPS for the current fiscal year.

Denali Therapeutics Company Profile

Denali Therapeutics Inc, a biopharmaceutical company, developing a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases. It pursues new treatments by assessing genetically validated targets, engineering delivery across the blood-brain barrier, and guiding development through biomarkers that demonstrate target and pathway engagement.